Skip to main content

Corteva, Inc.

For the period ended Dec 31, 2025. Filed Feb 12, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 12, 2026

CTVA$12.11+1.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Segment Information

NOTE 22 -SEGMENT INFORMATION

Corteva’s reportable segments reflect the manner in which its chief operating decision maker ("CODM") allocates resources and assesses performance, which is at the operating segment level (Seed and Crop Protection). The company's CODM is the Chief Executive Officer. The primary measure used by Corteva's CODM for purposes of allocating resources to the segments and assessing segment performance is segment operating EBITDA.

Segment operating EBITDA is primarily utilized in the annual planning and monthly forecasting processes. On a monthly basis, the CODM considers variances between comparable prior year actual results and current year actual or forecasted results when evaluating the company's success in delivering its innovative proprietary technology to farmers and monitoring of expected savings from cost and productivity actions. The CODM also utilizes segment operating EBITDA when evaluating the impacts of market-driven trends on segment performance, such as input costs and inflationary and currency impacts.

The company defines segment operating EBITDA as earnings (loss) (i.e., income (loss) from continuing operations before income taxes) before interest, depreciation, amortization, corporate expenses, non-operating (benefits) costs, foreign exchange gains (losses), and net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting, excluding the impact of significant items and separation costs. Non-operating (benefits) costs consists of non-operating pension and other post-employment benefit (OPEB) credits (costs), tax indemnification adjustments and environmental remediation and legal costs associated with legacy businesses and sites. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont that are recorded by the company as pre-tax income or expense. Net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting represents the non-cash net gain (loss) from changes in fair value of certain undesignated foreign currency derivative contracts. Upon settlement, which is within the same calendar year of execution of the contract, the realized gain (loss) from the changes in fair value of the non-qualified foreign currency derivative contracts will be reported in the respective segment results to reflect the economic effects of the foreign currency derivative contracts without the resulting unrealized mark to fair value volatility.

Corporate Profile

The company conducts its global operations through the following reportable segments:

Seed

The company's Seed segment is a global leader in developing and supplying commercial seed combining advanced germplasm and traits that offer maximum yield potential for farmers around the world. The segment is a leader in many key seed markets, including North America corn and soybeans, Europe corn and sunflower, as well as Brazil, India, South Africa and Argentina corn. The company offers seed and trait technologies that boost resilience to weather, pests, diseases, and herbicides used to manage weeds. Its digital solutions provide data-driven insights to help farmers optimize yield and profitability.

The Crop Protection segment serves the global agricultural input industry with products that protect against weeds, insects and other pests, and disease, and that support overall crop health both above and below ground via nitrogen management and seed-applied technologies. The segment offers crop protection solutions and digital solutions that provide farmers tools to improve productivity and profitability, and help keep fields free of weeds, insects and diseases. The segment is a leader in global herbicides, insecticides, nitrogen stabilizers, pasture and range management herbicides and biologicals and other nature-based products.

(In millions)SeedCrop ProtectionTotal
Net sales$9,898$7,503$17,401
Segment operating EBITDA2,6361,3503,986
Depreciation and amortization7804231,203
Purchases of property, plant and equipment377214591
Net sales$9,545$7,363$16,908
Segment operating EBITDA2,2191,2723,491
Depreciation and amortization8054221,227
Purchases of property, plant and equipment365232597
Net sales$9,472$7,754$17,226
Segment operating EBITDA2,1171,3743,491
Depreciation and amortization8143971,211
Purchases of property, plant and equipment332263595

Reconciliation of Segment Profitability

(In millions)SeedCrop ProtectionTotal
Net sales$9,898$7,503$17,401
Cost of goods sold4,5334,5859,118
Other expenses 12,7291,5684,297
Segment operating EBITDA$2,636$1,350$3,986
(In millions)SeedCrop ProtectionTotal
Net sales$9,545$7,363$16,908
Cost of goods sold4,8764,6369,512
Other expenses 12,4501,4553,905
Segment operating EBITDA$2,219$1,272$3,491
(In millions)SeedCrop ProtectionTotal
Net sales$9,472$7,754$17,226
Cost of goods sold4,9824,9139,895
Other expenses 12,3731,4673,840
Segment operating EBITDA$2,117$1,374$3,491
  1. Other expenses consist primarily of selling, general and administrative expenses and research and development expense, net of depreciation add-back.

Reconciliation to Consolidated Financial Statements

Income (loss) from continuing operations after income taxes to segment operating EBITDAFor the Year Ended December 31,
(In millions)202520242023
Income (loss) from continuing operations after income taxes$1,204$863$941
Provision for (benefit from) income taxes on continuing operations484412152
Income (loss) from continuing operations before income taxes$1,688$1,275$1,093
Depreciation and amortization1,2031,2271,211
Interest income(136)(132)(283)
Interest expense180233233
Exchange (gains) losses - net181284397
Non-operating (benefits) costs - net39174151
Mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges———
Significant items658315579
Separation costs35——
Corporate expenses138115110
Segment operating EBITDA$3,986$3,491$3,491

Significant Pre-tax (Charges) Benefits Not Included in Segment Operating EBITDA

The years ended December 31, 2025, 2024 and 2023, respectively, included the following significant pre-tax (charges) benefits which are excluded from segment operating EBITDA:

(In millions)SeedCrop ProtectionCorporateTotal
Restructuring and asset related charges - net 1$(4)$(135)$(7)$(146)
Bayer resolution 2(610)——(610)
Gain (loss) on sale of business, assets and equity investments 3,4—37—37
AltEn facility remediation charges 5(37)——(37)
Insurance proceeds 6—98—98
Total$(651)$—$(7)$(658)
(In millions)SeedCrop ProtectionCorporateTotal
Restructuring and asset related charges - net 1$(55)$(142)$(91)$(288)
Gain (loss) on sale of business, assets and equity investments 443—7
Inventory write-offs 42——2
Insurance proceeds 6—71—71
Estimated settlement expense 7—(101)—(101)
Acquisition-related costs 8—(6)—(6)
Total$(49)$(175)$(91)$(315)
(In millions)SeedCrop ProtectionCorporateTotal
Restructuring and asset related charges - net 1$(86)$(228)$(22)$(336)
Gain (loss) on sale of business, assets and equity investments 4410—14
Inventory write-offs 4(7)——(7)
Spare parts write-off 3—(12)—(12)
Estimated settlement expense 7—(204)—(204)
Acquisition-related costs 8—(45)—(45)
AltEn facility remediation charges 5(10)——(10)
Employee Retention Credit—3—3
Seed sale associated with Russia Exit 4,918——18
Total$(81)$(476)$(22)$(579)
  1. Includes restructuring plans and asset related charges as well as accelerated prepaid amortization expense. See Note 5 - Restructuring and Asset Related Charges - Net, to the Consolidated Financial Statements, for additional information.

  2. Consists of a charge relating to the resolution of litigation with Bayer. See Note 15 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements, for additional information.

  3. Incremental gains (losses) associated with activities related to the Crop Protection Operations Strategy Restructuring Program. Within gain (loss) on sale of business, assets and equity investments, a $23 million benefit was recorded for the year ended December 31, 2025.

  4. Incremental gains (losses) associated with activities related to the 2022 Restructuring Actions. Within gain (loss) on sale of business, assets and equity investments, such benefits are $14 million, $7 million and $14 million for the years ended December 31, 2025, 2024 and 2023, respectively.

  5. Relates to a charge to increase the remediation accrual at the AltEn facility relating to Corteva's estimated voluntary contribution to the solid waste and wastewater remedial action plans. See Note 15 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements, for additional information.

  6. Includes proceeds received related to prior significant items.

  7. Consists of estimated Lorsban® related charges.

  8. Relates to acquisition-related costs, including transaction and third-party integration costs associated with the completed acquisitions of Stoller and Symborg as well as the recognition of the inventory fair value step-up.

  9. Includes a benefit of $18 million for the year ended December 31, 2023, relating to the sale of seeds already under production in Russia when the decision to exit the country was made and that the company was contractually required to purchase. It consists of $71 million of net sales and $53 million of cost of goods sold for the year ended December 31, 2023.

Index to the Consolidated Financial Statements

Page(s)
Management's Reports on Responsibility for Financial Statements and Internal Control over Financial ReportingF-70
Report of Independent Registered Public Accounting Firm (PCAOB ID 238)F-71
Consolidated Financial Statements:
Consolidated Statements of Operations for the years ended December 31, 2025, 2024, and 2023F-73
Consolidated Statements of Comprehensive Income (Loss) for the years ended December 31, 2025, 2024 and 2023F-74
Consolidated Balance Sheets as of December 31, 2025 and 2024F-75
Consolidated Statements of Cash Flows for the years ended December 31, 2025, 2024, and 2023F-76
Consolidated Statements of Equity for the years ended December 31, 2025, 2024, and 2023F-77
Notes to the Consolidated Financial StatementsF-78
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.